ZimVie (ZIMV) Competitors $18.90 +0.02 (+0.11%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$18.90 0.00 (0.00%) As of 09/23/2025 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZIMV vs. LMAT, PRCT, AORT, EYE, ENOV, CNMD, NVCR, CDRE, BLFS, and BBNXShould you be buying ZimVie stock or one of its competitors? The main competitors of ZimVie include LeMaitre Vascular (LMAT), PROCEPT BioRobotics (PRCT), Artivion (AORT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), NovoCure (NVCR), Cadre (CDRE), BioLife Solutions (BLFS), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry. ZimVie vs. Its Competitors LeMaitre Vascular PROCEPT BioRobotics Artivion National Vision Enovis CONMED NovoCure Cadre BioLife Solutions Beta Bionics ZimVie (NASDAQ:ZIMV) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk. Which has stronger earnings and valuation, ZIMV or LMAT? LeMaitre Vascular has lower revenue, but higher earnings than ZimVie. ZimVie is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZimVie$449.75M1.19-$25.83M-$0.70-27.00LeMaitre Vascular$234.64M8.67$44.04M$2.0643.63 Does the media prefer ZIMV or LMAT? In the previous week, LeMaitre Vascular had 4 more articles in the media than ZimVie. MarketBeat recorded 5 mentions for LeMaitre Vascular and 1 mentions for ZimVie. LeMaitre Vascular's average media sentiment score of 1.63 beat ZimVie's score of 1.17 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ZimVie 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LeMaitre Vascular 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts prefer ZIMV or LMAT? ZimVie currently has a consensus target price of $17.75, suggesting a potential downside of 6.08%. LeMaitre Vascular has a consensus target price of $97.60, suggesting a potential upside of 8.60%. Given LeMaitre Vascular's stronger consensus rating and higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than ZimVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZimVie 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00LeMaitre Vascular 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Is ZIMV or LMAT more profitable? LeMaitre Vascular has a net margin of 20.08% compared to ZimVie's net margin of -4.39%. LeMaitre Vascular's return on equity of 13.67% beat ZimVie's return on equity.Company Net Margins Return on Equity Return on Assets ZimVie-4.39% 6.37% 3.34% LeMaitre Vascular 20.08%13.67%9.14% Which has more volatility & risk, ZIMV or LMAT? ZimVie has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Do insiders & institutionals hold more shares of ZIMV or LMAT? 95.6% of ZimVie shares are owned by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are owned by institutional investors. 5.4% of ZimVie shares are owned by company insiders. Comparatively, 9.5% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryLeMaitre Vascular beats ZimVie on 13 of the 16 factors compared between the two stocks. Get ZimVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ZIMV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZIMV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZIMV vs. The Competition Export to ExcelMetricZimVieMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$532.62M$10.70B$5.76B$10.50BDividend YieldN/A1.90%5.53%4.57%P/E Ratio-27.0020.5975.9626.62Price / Sales1.1938.02473.7891.77Price / Cash10.1624.5937.4661.85Price / Book1.373.4013.486.45Net Income-$25.83M$212.47M$3.29B$271.57M7 Day Performance0.11%0.14%1.83%2.61%1 Month Performance-0.26%-2.71%4.00%7.28%1 Year Performance18.79%-10.38%75.89%29.60% ZimVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZIMVZimVie1.1762 of 5 stars$18.90+0.1%$17.75-6.1%+18.3%$532.62M$449.75M-27.001,770Positive NewsLMATLeMaitre Vascular3.2754 of 5 stars$92.37+0.1%$97.60+5.7%-1.7%$2.09B$219.86M44.84490Positive NewsAnalyst ForecastPRCTPROCEPT BioRobotics2.7764 of 5 stars$38.00+2.3%$70.00+84.2%-51.2%$2.07B$224.50M-24.52430Positive NewsAORTArtivion2.5696 of 5 stars$39.74-2.4%$40.63+2.2%+62.5%$1.92B$388.54M-94.621,600Positive NewsEYENational Vision2.2151 of 5 stars$23.61+2.7%$24.73+4.7%+157.6%$1.82B$1.82B-131.1713,411ENOVEnovis3.9439 of 5 stars$32.35+2.0%$51.00+57.7%-28.4%$1.81B$2.11B-2.277,367Positive NewsCNMDCONMED4.5738 of 5 stars$51.76-2.1%$59.80+15.5%-35.6%$1.64B$1.33B14.663,900NVCRNovoCure4.3164 of 5 stars$12.72+4.7%$28.79+126.3%-21.4%$1.36B$630.16M-8.151,488Positive NewsCDRECadre2.2145 of 5 stars$32.72+0.6%$31.50-3.7%-0.8%$1.32B$567.56M34.812,284Positive NewsBLFSBioLife Solutions2.9966 of 5 stars$25.80+1.1%$31.29+21.3%-0.2%$1.22B$82.25M-214.98440Positive NewsBBNXBeta Bionics1.1153 of 5 stars$25.31-4.2%$22.56-10.9%N/A$1.15B$65.12M0.00294Analyst Forecast Related Companies and Tools Related Companies LeMaitre Vascular Competitors PROCEPT BioRobotics Competitors Artivion Competitors National Vision Competitors Enovis Competitors CONMED Competitors NovoCure Competitors Cadre Competitors BioLife Solutions Competitors Beta Bionics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZIMV) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZimVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZimVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZIMV Stock Alerts